These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23236346)

  • 1. Monitoring HIV viral load in resource limited settings: still a matter of debate?
    Arnedo M; Alonso E; Eisenberg N; Ibáñez L; Ferreyra C; Jaén A; Flevaud L; Khamadi S; Roddy P; Gatell JM; Dalmau D;
    PLoS One; 2012; 7(12):e47391. PubMed ID: 23236346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
    Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
    J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
    Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
    Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
    Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa.
    Green TN; Archary M; Gordon ML; Padayachi N; Lie Y; Anton ED; Reeves JD; Grobler A; Bobat R; Coovadia H; Ndung'u T
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):324-32. PubMed ID: 21819257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.
    Ferradini L; Laureillard D; Prak N; Ngeth C; Fernandez M; Pinoges L; Puertas G; Taburet AM; Ly N; Rouzioux C; Balkan S; Quillet C; Delfraissy JF
    AIDS; 2007 Nov; 21(17):2293-301. PubMed ID: 18090277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
    Ferradini L; Jeannin A; Pinoges L; Izopet J; Odhiambo D; Mankhambo L; Karungi G; Szumilin E; Balandine S; Fedida G; Carrieri MP; Spire B; Ford N; Tassie JM; Guerin PJ; Brasher C
    Lancet; 2006 Apr; 367(9519):1335-42. PubMed ID: 16631912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
    Dagnra AY; Vidal N; Mensah A; Patassi A; Aho K; Salou M; Monleau M; Prince-David M; Singo A; Pitche P; Delaporte E; Peeters M
    J Int AIDS Soc; 2011 Jun; 14():30. PubMed ID: 21663632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
    Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
    Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment failure predicts mortality in rural Tanzania.
    Pettersen PS; Brox IK; Naman E; Bruun JN; Dyrhol-Riise AM; Trøseid M; Johannessen A
    Int J STD AIDS; 2015 Aug; 26(9):633-9. PubMed ID: 25122578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
    Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Defo VF; Moudourou S; Fokam J; Kouanfack C; Torimiro J
    J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.